
Nvidia Just Became the World's First $4 Trillion Stock. This Artificial Intelligence (AI) Giant -- Which Is up 686,000% Since Its IPO -- Might Be Next.
Following two incredible years of growth, thanks to artificial intelligence (AI), Nvidia became the world's first $4 trillion company on July 9.
Microsoft has a market capitalization of $3.7 trillion, so it could be the next member of the ultra-exclusive $4 trillion club.
Microsoft stock could get there in the next few months if the incredible momentum in its AI products and services continues.
10 stocks we like better than Microsoft ›
Nvidia supplies the world's best artificial intelligence (AI) chips for data centers. Demand is heavily outstripping supply, sending the company's sales -- and its stock price -- surging over the last couple of years. In fact, on July 9, Nvidia became the first company in history to achieve a market capitalization of $4 trillion.
But Microsoft (NASDAQ: MSFT) is nipping at Nvidia's heels in terms of valuation. Its stock has soared by a whopping 686,858% since its initial public offering (IPO) in 1986, and the company's market cap is now over $3.7 trillion.
In other words, Microsoft stock needs to gain only 8% more to place the company alongside Nvidia in the $4 trillion club. Here's why its growing presence in AI software and infrastructure could fuel that move.
Microsoft developed a powerful AI assistant called Copilot
Since 2019, Microsoft has invested around $14 billion in ChatGPT developer OpenAI. It has used the start-up's latest large language models (LLMs) to craft its own AI assistant, called Copilot, which is embedded in almost all of its flagship software products. Copilot is accessible for free through Windows, Bing, and Edge, and it's available as a paid add-on in a host of other products, creating new revenue streams for Microsoft.
For instance, enterprises can add Copilot to their Microsoft 365 subscription for an additional monthly fee, where it can boost their employees' productivity in applications such as Word, Excel, and Outlook. Enterprises around the world pay for more than 400 million 365 licenses, so the Copilot add-on could generate billions of dollars in recurring revenue over time. During the fiscal 2025 third quarter (ended March 31), the number of organizations using Copilot for 365 tripled compared to the year-ago period, so uptake has certainly been rapid so far.
Then there is the Copilot Studio platform, which enables organizations to create custom AI agents to suit their workflows. For example, a business can create one agent to deal with customer service queries on their website and another agent to help manage their logistics network. The platform had over 230,000 customers at the end of the fiscal 2025 third quarter, and I expect that number to climb significantly as AI adoption becomes more widespread.
AI could drive a long-term acceleration in Azure cloud revenue
Microsoft's AI opportunity in the cloud might be even bigger than the opportunity created by Copilot. Its cloud computing platform, Azure, offers hundreds of digital services to enterprises, helping them with everything from simple data storage and web hosting to more complex tasks such as software development. Now, it provides a growing list of tools that enterprises need to fuel their AI ambitions.
Microsoft operates centralized data centers filled with the latest graphics processing units (GPUs) from suppliers like Nvidia, and it rents the computing capacity to enterprises that use it to train and deploy AI applications. Microsoft spent over $60 billion to build AI infrastructure during the first three quarters of fiscal 2025 to meet demand. It sounds like a massive number, but CFO Amy Hood says there is an eye-popping $315 billion order backlog from customers who are waiting for Microsoft to bring more data centers online.
Besides AI hardware, Azure also offers access to the latest third-party LLMs from leading developers like OpenAI. Enterprises can plug their internal data into these models to create custom AI software to suit their needs. Using a ready-made LLM is much faster (not to mention cheaper) than building a model from scratch.
Azure revenue grew by 33% year over year during the fiscal 2025 third quarter, which marked an acceleration from the 31% growth it delivered in the second quarter three months earlier. AI services accounted for a record-high 16 percentage points of that growth, which highlights just how important this segment has become to Microsoft's cloud division. In fact, if not for AI, Azure's revenue growth would probably be decelerating sharply.
Microsoft could be the next member of the $4 trillion club
Microsoft's $3.7 trillion market cap makes it the world's second-largest company behind Nvidia, and it's comfortably ahead of third-place Apple, which is worth $3.2 trillion. Microsoft stock isn't cheap right now, so it may take some time to gain the final 8% it needs to reach the $4 trillion milestone, but I predict it will beat Apple and every other company to the punch.
At the time of this writing, Microsoft stock is trading at a price-to-earnings (P/E) ratio of 38.7, which is a premium to its five-year average of 33.4. However, Wall Street's consensus estimate (provided by Yahoo! Finance) suggests the company's earnings per share could grow by 13% during fiscal 2026 (which officially started on July 1), placing its stock at a forward P/E ratio of 33.1:
MSFT PE Ratio data by YCharts. PE Ratio = price-to-earnings ratio.
In other words, Microsoft stock would have to climb by around 17% over the next 12 months just to maintain its current P/E ratio of 38.7, which isn't out of the question, considering the strong momentum in the company's AI products and services. Since the stock market is a forward-looking machine, I think it's possible for Microsoft shares to climb by 8% over the next six months or so, provided its quarterly financial results continue to come in as expected (or better).
As a result, I think Microsoft is likely to be the next member of the $4 trillion club.
Should you invest $1,000 in Microsoft right now?
Before you buy stock in Microsoft, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!*
Now, it's worth noting Stock Advisor 's total average return is1,047% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
5 minutes ago
- Globe and Mail
Markets Await Consumer Sentiment Reading
Pre-market futures are up again as a very eventful trading week winds to a close. The Dow is currently +0.12%, the S&P 500 is +0.09% and the Nasdaq +0.16% at this hour. The small-cap Russell 2000 is shooting to another orbit this morning, +0.52%. It now leads all major indexes for the past week of trading, as it still tries to catch up with the other indexes year to date. Bond yields have remained fairly steady through a thorough barrage of economic reports Q2 earnings releases, and open speculation about the future tenure of Fed Chair Jerome Powell. The 10-year yield is up a mere 3 basis points (bps) from last Friday, +4.44%. The 2-year continues to shrink gradually, now +3.88%, while the 30-year remains hanging onto its recent 5-handle: +5.00%. Housing Starts & Building Permits Improve, Stay Muted Housing Starts for the month of June remained historically low, coming in slightly ahead of projections to 1.32 million seasonally adjusted, annualized units, up from 1.256 million the prior month, which was the worst performance on new housing starts in five years. Multi-year highs back in April 2022 were 500K higher than they are presently. Building Permits of 1.397 million were also up a bit month over month, from 1.394 million reported for May, which was the weakest level of permits for new homebuilding since June 2020. Back in January of 2022, we were close to 2 million building permits per month — but that was prior to the Fed raising interest rates, which directly sent mortgage rates surging higher. Q2 Earnings Beats for 3M, AmEx & Schwab Minnesota-based industrial conglomerate 3M (MMM) shares are up +3% on the company's beat-and-raise in its Q2 report ahead of today's opening bell. Earnings of $2.16 per share outshone the Zacks consensus of $2.01, for an earnings surprise of +7.46%. Revenues of $6.2 billion in the quarter improved over the $6.12 billion forecast. Earnings guidance for full-year 2025 was also raised to a range of $7.75-8.00 per share. American Express (AXP) also surpassed expectations in its Q2 report this morning, with earnings of $4.08 per share beating the $3.86 expected and the $3.49 per share posted in the year-ago quarter. Revenues of $17.9 billion topped the $17.69 billion estimate, for year-over-year growth of +9%. Shares are flat in today's pre-market, up +6.25% year to date. Financial services major Charles Schwab (SCHW) is having an even better morning, with shares up +5% in the pre-market, adding to its +26% growth year to date, with solid beats on both top and bottom lines in this morning's Q2 report. Earnings of $1.14 per share on revenues of $5.85 billion surged past the $1.09 per share and $5.70 billion, respectively, in the Zacks consensus. What to Expect from the Stock Market Today After today's open, we'll see a preliminary print on Consumer Sentiment for July. This is expected to improve to 61.8 from the prior read of 60.7, which tracks with the present narrative of a healthy environment. Q2 earnings season overall has provided a rosier outlook, and most of the fears of tariffs sandbagging the economy have dissipated. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 3M Company (MMM): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report The Charles Schwab Corporation (SCHW): Free Stock Analysis Report


Globe and Mail
5 minutes ago
- Globe and Mail
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion by the end of the decade. Oncology, at present, comprises around 27% of J&J's total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches. Though the $50 billion target was well above consensus, J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. Meanwhile, J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ's oncology sales. In the five years from 2019 to 2024, J&J's oncology sales have doubled from $10.7 billion in 2019 to $20.8 billion in 2024. To achieve the $50 billion target in the next 5-6 years, the company needs to more than double its sales from 2024 levels. Though quite optimistic, the target is not unachievable. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. For AstraZeneca, oncology sales now comprise around 41% of total revenues. AstraZeneca's strong oncology sales growth is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI1inhibitor, Opdivo, which accounts for around 20% of its total revenues. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 14.6% in the year-to-date period compared with an increase of 1.5% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.97 forward earnings, slightly lower than 15.04 for the industry. The stock is also trading below its five-year mean of 15.70. The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.66 over the past 30 days, while that for 2026 has risen from $10.98 to $11.13 over the same timeframe. J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report


Globe and Mail
5 minutes ago
- Globe and Mail
Buy, Sell or Hold Alphabet Stock? Key Tips Ahead of Q2 Earnings
Alphabet GOOGL is set to report second-quarter 2025 results on July 23. For second-quarter 2025, the Zacks Consensus Estimate for earnings is pegged at $2.13 per share, up by a penny over the past 30 days and indicates 12.7% year-over-year growth. The consensus mark for second-quarter revenues is pegged at $79.22 billion, indicating growth of 11.02% from the year-ago quarter's reported figure. Alphabet has an impressive earnings surprise history. GOOGL's earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 14.64%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Alphabet Inc. Price and EPS Surprise Alphabet Inc. price-eps-surprise | Alphabet Inc. Quote Let's see how things have shaped up for the upcoming announcement: Growing AI Usage in Search to Aid GOOGL's Q2 Results Alphabet's to-be-reported quarterly results are expected to benefit from solid momentum in Search and Cloud businesses. The integration of Generative AI (Gen AI) technology into the search engine has been benefiting Google Search. AI-powered Circle to Search is now available on more than 300 million Android devices, with people using it to shop, translate text, and learn more about the world around them. Circle to Search is driving additional Search and is gaining popularity among younger users. The addition of AI mode expands AI Overview's advanced reasoning, thinking and multimodal capabilities. The Zacks Consensus Estimate for second-quarter 2025 Search and other revenues is pegged at $52.36 billion, indicating 8% growth over the figure reported in the year-ago quarter. GOOGL Cloud Gaining Market Share Alphabet has been rapidly growing in the booming cloud computing market. Google Cloud has solidified its position as the third-largest provider in the highly competitive cloud infrastructure market against Amazon 's AMZN cloud arm, Amazon Web Services (AWS), and Microsoft' s MSFT Azure. The solid adoption of the Google Cloud Platform and Google Workspace is expected to have driven growth in the Google Cloud segment. According to Synergy Research Group data, Google Cloud, along with Microsoft, is gaining market share, while AWS continues to lead with a 29% market share in the first quarter of 2025. Alphabet and Microsoft had 22% and 12% market share, respectively. The consensus mark for second-quarter 2025 Google Cloud revenues is pegged at $13.04 billion, indicating 26% growth over the figure reported in the year-ago quarter. However, GOOGL is suffering from a lack of capacity, and until new capacity comes online in 2025, cloud revenues are expected to see increased variability. This is expected to have hurt Alphabet's Google Cloud revenues in the to-be-reported quarter. GOOGL Shares Lag Sector, Industry Image Source: Zacks Investment Research Alphabet's shares have declined 3.1% year to date, underperforming the Zacks Internet Services industry and the Zacks Computer & Technology sector. Over the same timeframe, the sector has returned 9.5% while the industry has dropped 0.9%. GOOGL Stock's Performance GOOGL shares are overvalued, as suggested by Value Score C. Currently, GOOGL is trading at a premium, with a forward 12-month Price/Sales of 6.43X compared with the industry's 5.49X. Price/Sales Ratio (F12M) Technically, GOOGL shares are displaying a bullish trend as they trade above the 50-day and 200-day moving averages. GOOGL Trades Above 50-day & 200-day SMAs Cloud Growth to Drive GOOGL Prospects Alphabet is benefiting from an expanding clientele and rich partner base. Google Cloud is benefiting from its partnership with NVIDIA NVDA. Google Cloud was the first cloud provider to offer NVIDIA's B200 and GB200 Blackwell GPUs and will be offering its next-generation Vera Rubin GPUs. Google Cloud is becoming a preferred choice for enterprises planning to deploy AI agents thanks to the Agent Development Kit and a low-code tool offering Agent Designer. The addition of Wiz to Google Cloud will boost competitive prowess against the likes of Amazon and Microsoft in the cloud computing space. Google Cloud's expanding clientele is expected to boost Alphabet's top line. Google Cloud is now expanding its footprint based on the latest deals with Ecobank in Africa and BBVA. BBVA's deal with Google Cloud will enable Alphabet to deploy Google Workspace with Gemini across the global operations of the bank. Meanwhile, the Ecobank collaboration aims at transforming financial services with advanced analytics and AI and driving digital empowerment across Africa. This offers a significant growth opportunity for Google Cloud in one of the most underpenetrated regions of the globe. GOOGL Stock: Buy, Sell or Hold Ahead of Q2? Alphabet's growing Gen AI capabilities present a potential catalyst for future growth. Its dominant position in the Search market is a strong growth driver. However, a stretched valuation, stiff competition in the cloud space and growing regulatory headwinds make GOOGL shares risky for investors ahead of second-quarter 2025 results. Alphabet currently has a Zacks Rank #3 (Hold), suggesting that it may be wise to wait for a more favorable entry point in the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report